Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
May 01, 2023 07:30 ET
|
Atsena Therapeutics
ATSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in the central retina/fovea Initiation of Phase I/II...
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
April 25, 2023 07:30 ET
|
Atsena Therapeutics
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post treatmentData presented at ARVO 2023 DURHAM, N.C.,...
Atsena Therapeutics Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101 to be Presented at ARVO 2023 Annual Meeting
April 11, 2023 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting
February 08, 2023 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
December 07, 2022 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
November 07, 2022 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
October 03, 2022 07:30 ET
|
Atsena Therapeutics
ATSN-101 demonstrated clinically meaningful improvements in vision with no drug-related serious adverse events Data presented at the American Academy of Ophthalmology 2022 Annual Meeting DURHAM,...
Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
September 21, 2022 07:30 ET
|
Atsena Therapeutics
Data from Phase I/II trial of ATSN-101 in patients with GUCY2D-associated Leber congenital amaurosis (LCA1) to be presented DURHAM, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a...
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
July 27, 2022 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting
May 02, 2022 07:30 ET
|
Atsena Therapeutics
DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...